ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      4,967.23
      -0.88%
      US Tech 100
      16,564.00
      -2.20%
      Dow Jones
      37,986.40
      0.56%
      Brent Oil
      86.625
      0.24%
      Bitcoin
      63,533.36
      0.03%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. AMEX
      6. Actinium Pharmaceuticals Inc (ATNM)

      7. Actinium Pharmaceuticals Inc (ATNM) News

      ATNM

      Actinium Pharmaceuticals (ATNM)

      Actinium Pharmaceuticals Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:AMEX:ATNM
      DateTimeSourceHeadlineSymbolCompany
      04/18/20248:00AMPR Newswire (US)Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual MeetingAMEX:ATNMActinium Pharmaceuticals Inc
      04/01/20248:00AMPR Newswire (US)Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European Bone Marrow Transplant AnnualAMEX:ATNMActinium Pharmaceuticals Inc
      03/26/20247:18AMPR Newswire (US)Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell TherapyAMEX:ATNMActinium Pharmaceuticals Inc
      03/11/20247:30AMPR Newswire (US)Actinium Pharmaceuticals Launches Actinium-225 Focused Strategic Initiative to Leverage Proprietary Cyclotron Based Manufacturing Technology to Address Growing Market DemandAMEX:ATNMActinium Pharmaceuticals Inc
      02/26/20247:30AMPR Newswire (US)Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTAMEX:ATNMActinium Pharmaceuticals Inc
      02/23/20247:30AMPR Newswire (US)Actinium Highlights Improved Survival with Iomab-B in TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients in the SIERRA Trial and Other Presentations at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBAMEX:ATNMActinium Pharmaceuticals Inc
      02/09/20244:30PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]AMEX:ATNMActinium Pharmaceuticals Inc
      02/06/202412:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessAMEX:ATNMActinium Pharmaceuticals Inc
      02/02/20245:03PMEdgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]AMEX:ATNMActinium Pharmaceuticals Inc
      01/02/20247:30AMPR Newswire (US)Actinium Announces Acceptance of Five Abstracts for Presentation at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®AMEX:ATNMActinium Pharmaceuticals Inc
      12/29/20235:24PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:ATNMActinium Pharmaceuticals Inc
      12/29/20235:20PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:ATNMActinium Pharmaceuticals Inc
      12/29/20235:18PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:ATNMActinium Pharmaceuticals Inc
      12/29/20235:17PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:ATNMActinium Pharmaceuticals Inc
      12/29/20235:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:ATNMActinium Pharmaceuticals Inc
      12/11/20238:15AMPR Newswire (US)Actinium Announces Iomab-B Produces High Response Rates and Significant Improvement in Overall Survival in Relapsed Refractory AML Patients with Active Disease Overcoming TP53 MutationAMEX:ATNMActinium Pharmaceuticals Inc
      12/11/20237:45AMPR Newswire (US)Actinium's Four Presentations at ASH Highlight the Positive Outcomes for Iomab-B and Actimab-A in Patients with Relapsed or Refractory Acute Myeloid LeukemiaAMEX:ATNMActinium Pharmaceuticals Inc
      12/08/20238:00AMPR Newswire (US)Actinium to Highlight Broad Potential of Targeted Radiotherapies Iomab-B and Actimab-A for Relapsed or Refractory and Elderly Acute Myeloid Leukemia Patients at the 65th ASH Annual Meeting & ExpositionAMEX:ATNMActinium Pharmaceuticals Inc
      12/01/20235:00PMEdgar (US Regulatory)Form 8-K - Current reportAMEX:ATNMActinium Pharmaceuticals Inc
      11/09/20235:09PMEdgar (US Regulatory)Form ARS - Annual Report to Security HoldersAMEX:ATNMActinium Pharmaceuticals Inc
      11/09/20235:05PMEdgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsAMEX:ATNMActinium Pharmaceuticals Inc
      11/06/20237:30AMPR Newswire (US)Actinium Presents Preclinical Data at SITC Demonstrating Actimab-A's Potential to Restore T Cell Immunity in the Solid Tumor Microenvironment Supporting Immunotherapy CombinationsAMEX:ATNMActinium Pharmaceuticals Inc
      11/02/20234:15PMPR Newswire (US)Actinium Pharmaceuticals to Attend Bio-Europe Munich 2023AMEX:ATNMActinium Pharmaceuticals Inc
      11/02/20239:05AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:ATNMActinium Pharmaceuticals Inc
      11/02/20239:05AMPR Newswire (US)Actinium Announces Oral Presentation at ASH Annual Meeting Highlighting Iomab-B Treatment Significantly Increased Median Overall Survival in Relapsed or Refractory AML Patients with Highly Unfavorable TP53 Gene Mutation in the Phase 3 SIERRA TrialAMEX:ATNMActinium Pharmaceuticals Inc
      10/04/20237:30AMPR Newswire (US)Actinium Announces NIH Grant Extension to Advance Clinical Development of Next-Generation CD45 Targeted Conditioning Agent Iomab-ACT with Memorial Sloan Kettering's CAR-T Cell TherapyAMEX:ATNMActinium Pharmaceuticals Inc
      09/27/20239:05AMPR Newswire (US)Actinium Pharma Highlights Abstract Accepted for Poster Presentation at the SITC 38th Annual MeetingAMEX:ATNMActinium Pharmaceuticals Inc
      09/07/20238:40AMPR Newswire (US)Actinium Pharma Presents Survival Data from Extended Follow-Up from Actimab-A + CLAG-M Trial and Preclinical Data Supporting Program Expansion with FLT3 Inhibitor Combinations at SOHOAMEX:ATNMActinium Pharmaceuticals Inc
      08/31/20237:00AMPR Newswire (US)Actinium Pharma Highlights Three Abstracts Accepted for Poster Presentation at the SOHO 2023 Annual MeetingAMEX:ATNMActinium Pharmaceuticals Inc
      08/21/20237:00AMPR Newswire (US)Actinium Pharma Highlights Abstracts Accepted for Oral and Poster Presentation at the EANM 2023 CongressAMEX:ATNMActinium Pharmaceuticals Inc
       Showing the most relevant articles for your search:AMEX:ATNM